Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2252W HIGH $2.57
Volume
1.53 M
Value Traded
358.18 K
Short % Float
4.28%
-28.8%Week
-30.87%1 Month
-79.06%3 Month
-78.27%6 Month
-91.17%5 Year
-91.17%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.47 M
EPS (TTM)
-1.74
P/E Ratio
-
Ent. Value
-40.20 M
Total Shares
67.78 M
Float Shares
53.32 M
Insiders
21.33%
Institutions
50.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TCRX Catalyst Timeline
Dated clinical, regulatory and corporate events for TScan Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TScan Therapeutics, Inc.
477Total events
15Upcoming
60Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲IND Enabling CompletePreclinical
Two in vivo TCR-T candidates advanced to IND-enabling studies
solid tumorssource ↗
▼Enrollment PausedTSC-101Trial
Paused further enrollment in Phase 3 ALLOHA-2 study
heme malignanciessource ↗
▼Trial PausedTSC-101Trial
Paused further enrollment in Phase 3 ALLOHA-2 study of TSC-101
heme malignanciessource ↗
▲Full ResultsTSC-101Clinical Data
Updated data from Cohort C of Phase 1 ALLOHA study: 100% complete donor chimerism
heme malignanciessource ↗
▲Additional DataClinical Data
Shared positive initial data from Cohort C of Phase 1 ALLOHA study
▲First Patient DosedTSC-101Trial
First patient infused with TSC-101 in Phase 3 ALLOHA-2 trial
acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)source ↗
◆Trial InitiationTSC-102Trial
Plans to initiate Phase 1 trial for TSC-102-A01
hematologic malignanciessource ↗
◆Trial InitiationTSC-102Trial
Plans to initiate Phase 1 trial for TSC-102-A03
hematologic malignanciessource ↗
◆Oral PresentationPresentation
TScan Therapeutics to participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference fireside chat
◆Oral PresentationPresentation
Virtual KOL event featuring Ran Reshef to discuss Cohort C data and Phase 3 plans
▲Topline ReadoutTSC-101Clinical Data
Initial data from Cohort C of ALLOHA Phase 1 study
heme malignancies undergoing allogeneic hematopoietic cell transplantationsource ↗
▲Partnership / LicenseTSC-101Corporate
Cellares and TScan Therapeutics announce agreement to evaluate automated manufacturing of TSC-101
hematologic malignanciessource ↗
◆Trial InitiationTSC-101Trial
First patient enrollment in Phase 3 ALLOHA-2 study
heme malignancies undergoing allogeneic hematopoietic cell transplantationsource ↗
▲Enrollment MilestoneTSC-101Trial
Initial data reported from Cohort C of Phase 1 ALLOHA trial
acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)source ↗
▲Interim AnalysisTSC-101Trial
Initial data from Cohort C of Phase 1 ALLOHA trial reported
AML and MDSsource ↗
◆Poster PresentationPresentation
Poster presentation at ASGCT 29th Annual Meeting: Novel CD45-targeted TCR-T cell therapies
cancersource ↗
◆Poster PresentationPresentation
Abstract accepted for poster presentation at ASGCT 29th Annual Meeting
◆Oral PresentationPresentation
TScan Therapeutics to participate in fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆Trial InitiationTSC-101Trial
Launch pivotal trial for TSC-101 in AML and MDS
acute myeloid leukemia and myelodysplastic syndromessource ↗
◆Topline ReadoutTSC-101Clinical Data
Share safety and early chimerism data from Cohort C
heme malignanciessource ↗
◆Oral PresentationPresentation
TScan Therapeutics to present at TD Cowen 46th Annual Health Care Conference
▲Enrollment CompleteTSC-101Trial
Completed enrollment in Cohort C of Phase 1 ALLOHA trial
heme malignanciessource ↗
▲Enrollment CompleteTSC-101Trial
Enrollment completed in Cohort C of ALLOHA Phase 1 trial
hematologic malignanciessource ↗
●Poster PresentationTSC-101Presentation
Poster presented at 2026 Tandem Meetings
hematologic malignanciessource ↗
◆Full ResultsClinical Data
Safety and efficacy data on patients infused to date in PLEXI-T trial to be shared
solid tumorssource ↗
◆IND SubmissionTSC-102IND
File two INDs for TSC-102 (A*03:01 and A*01:01) in Q1 2026
Hematologic malignanciessource ↗
◆Trial InitiationTrial
Initiate registration trial for heme program pending regulatory feedback
acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromesource ↗
◆Long Term DataTSC-100Clinical Data
Two-year clinical and translational data in heme program
acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromesource ↗
◆Long Term DataTSC-101Clinical Data
Two-year clinical and translational data in heme program
acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromesource ↗
◆Topline ReadoutClinical Data
Response data for multiplex therapy in solid tumors
solid tumorssource ↗
●Manufacturing MilestoneCMC / Inspection
Transfer commercial heme manufacturing process to CDMO
◆Oral PresentationPresentation
Virtual KOL event to discuss updated data from ALLOHA Phase 1 trial and future market opportunities
heme malignanciessource ↗
◆Oral PresentationTSC-101Presentation
Virtual KOL event to discuss ASH data and manufacturing process
heme malignanciessource ↗
◆Poster PresentationTSC-101Presentation
Updated results from ALLOHA Phase 1 trial presented at ASH 2025
heme malignanciessource ↗
◆Oral PresentationTSC-101Presentation
Updated results from ALLOHA trial presented at conference
AML, ALL, or MDSsource ↗
◆Poster PresentationTSC-101Presentation
Poster presentation at 67th ASH Annual Meeting including two-year relapse data on initial patients from ALLOHA Phase 1 trial evaluating TSC-101
heme malignanciessource ↗
●Oral PresentationPresentation
Presented preclinical data for lead autoimmunity programs at ACR Convergence 2025
Autoimmunity (systemic sclerosis, ulcerative colitis, ankylosing spondylitis, birdshot uveitis)source ↗
▲Oral PresentationTSC-101Presentation
Positive updated data from ALLOHA Phase 1 heme trial presented at ASH 2025
hematologic malignanciessource ↗
◆Oral PresentationTSC-100Presentation
Additional data from Phase 1 trial including two-year relapse data
AML, ALL, MDSsource ↗
◆Oral PresentationPresentation
TScan Therapeutics to participate in fireside chat at Guggenheim 2nd Annual Healthcare Innovation Conference
Past FDA Catalysts and PDUFA Decisions
How TCRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | PLEXI-T | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$2M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 61%
Micro Cap(rank 402 of 658)
Percentile Rank
TScan Therapeutics, Inc. faces pipeline headwinds (33/100), with $194M risk-adjusted pipeline value, led by TSC-204-A0201 in Head and Neck Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TSC-204-A0201 Monoclonal antibodyNCT05973487 | Head and Neck Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 840 | Dec 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every TCRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TSC-101 RMAT | hematologic malignancies | Phase 1 | 2026-03-04 | TSC-101 was well-tolerated with no dose-limiting toxicities observed.; Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23); overall survival (HR=0.61; p=0.52); 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free compared to 1/4 (25%) in the control arm.Read More | TScan Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (unaudited, in thousands, except share amount)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LPDirector | Grant/Award | 67,000 67,000 held | $0.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TCRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.1 % (-50 %) | 5.45 M | 5.56 M |
TCRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TCRX ranks across every disease it competes in
Competitive Position is a premium feature
See how TCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTCRX News
TCRX▼ -42.8%on this news
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics has announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, advancing two TCR-T candidates to IND-enabling studies. The company reported complete donor chimerism in all patients from Cohort C of its Phase 1 ALLOHA study. However, enrollment in the Phase 3 ALLOHA-2 study is paused due to insufficient capital, leading to a significant workforce reduction.
Read more →TCRXTScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics has reported its financial results for the second quarter of 2026, highlighting significant progress in its clinical trials. The company has dosed the first patient in the Phase 3 ALLOHA-2™ study, with topline results anticipated by mid-2028. Additionally, positive initial data from the Phase 1 ALLOHA™ study supports their manufacturing process, and their financial position is stable through mid-2027.
Read more →TCRXTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics has announced the first patient has been dosed with TSC-101 in the Phase 3 ALLOHA-2 trial, aimed at preventing relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. The trial evaluates TSC-101's efficacy and safety following allogeneic hematopoietic cell transplantation. Initial data from earlier studies show promising results, enhancing confidence in the ongoing trial.
Read more →TCRXTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
TScan Therapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company will host a fireside chat at 11:30 a.m. Eastern Time, which will be available via webcast. TScan is developing TCR-engineered T cell therapies for cancer treatment, focusing on hematologic malignancies and solid tumors.
Read more →TCRX▼ -6%on this newsshared move
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101, showing that 11 of 14 patients achieved complete donor chimerism within approximately three weeks. The therapy was well-tolerated, and the company plans to enroll its first patient in the Phase 3 ALLOHA-2 study this month. The results support the efficacy of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.
Read more →TCRXCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Cellares and TScan Therapeutics have entered into an agreement to evaluate the automated manufacturing of TSC-101, a treatment aimed at patients with hematologic malignancies. This collaboration seeks to enhance the production process of TSC-101, potentially improving access for patients. Further details on the implications of this partnership are yet to be disclosed.
Read more →TCRXTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics reported its Q1 2026 financial results, highlighting key milestones for its T cell receptor therapies. The company plans to initiate a Phase 3 study of TSC-101 and a Phase 1 study of TSC-102-A01 and TSC-102-A03 later this year. Despite a decrease in revenue and a net loss, TScan's cash reserves are expected to support operations into 2027.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics has announced the acceptance of an abstract for a poster presentation at the ASGCT 29th Annual Meeting, scheduled for May 11-15 in Boston. The presentation will focus on novel CD45-targeted TCR-T cell therapies aimed at eliminating residual disease and preventing relapse after allogeneic hematopoietic cell transplantation. The company plans to share the presentation materials on its website post-event.
Read more →TCRXTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
TScan Therapeutics, a clinical-stage biotech company, will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The event will feature a fireside chat at 3:00 p.m. Eastern Time, with a webcast available on the company's website. TScan is focused on developing TCR-engineered T cell therapies for cancer treatment.
Read more →TCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its hematologic malignancies program. The company presented positive data from the ALLOHA Phase 1 heme trial and received FDA clearance for two new TCR-T therapy candidates. Despite a net loss, TScan's financial position remains strong, with sufficient cash to support operations into 2027.
Read more →TCRXTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics has completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial, utilizing a new commercial-ready manufacturing process. The FDA has cleared IND applications for two new candidates, TSC-102-A01 and TSC-102-A03, which target specific HLA types. The company plans to initiate a Phase 1 study for these candidates in the latter half of 2026, aiming to expand its treatment options for hematologic malignancies.
Read more →TCRX▲ +5.7%on this newsshared move
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
TScan Therapeutics, a clinical-stage biotech firm, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The event will include a hybrid presentation and an analyst-led Q&A session. TScan focuses on developing T cell receptor-engineered therapies for cancer, with ongoing trials for hematologic malignancies and solid tumors.
Read more →TCRXDisclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but n
TScan Therapeutics has presented forward-looking statements about its clinical programs and upcoming plans. The company highlights promising data from its TCR-T therapy candidate, TSC-101, which shows durable responses among patients. TScan also aims to launch a pivotal study for TSC-101 in Q2 2026 and expand its market opportunities with additional IND submissions. The report emphasizes the need for continued monitoring of risks associated with developing innovative therapies.
Read more →TCRX▼ -7.4%on this news
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics reported positive updated data from its ALLOHA Phase 1 trial for TSC-101 at the ASH Annual Meeting. The treatment demonstrated significant improvements in relapse-free and overall survival rates among patients with hematologic malignancies. Notably, all patients who reached a two-year follow-up remained relapse-free. The company plans to initiate a pivotal study in 2026.
Read more →TCRX▲ +6.9%on this newsshared move
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
TScan Therapeutics will host a virtual KOL event on December 8 to discuss updates from the ALLOHA Phase 1 trial and future market opportunities for its TCR-T therapies. The event will highlight two-year relapse data from the trial and the company's enhanced manufacturing process. The discussion will also cover the unmet medical needs in hematologic malignancies.
Read more →TCRXTScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics reported its Q3 2025 financial results, highlighting a productive FDA meeting that established a pivotal trial design for TSC-101. The company is prioritizing its heme malignancies program while also developing TCR-T therapies for solid tumors. Despite a net loss increase, TScan's cash position is strong, expected to support operations through mid-2027.
Read more →About TScan Therapeutics, Inc.
Headquarters830 WINTER STREET, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next TCRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime